



27 September 2021

ASX ANNOUNCEMENT

SOZO Heart Failure Program Initiated at AdvocateAuroraHealth

ImpediMed Limited (ASX:IPD) is pleased to announce the inaugural SOZO Heart Failure Program has been established at Advocate Health Care's Heart Institute, Chicago Illinois under the guidance of Dr Ali Valika, MD, an interventional cardiology specialist board certified in Advanced Heart Failure and Transplant Cardiology.

AdvocateAuroraHealth® consists of 26 hospitals and over 500 sites of care. Advocate Health Care in Illinois and Aurora Health Care in Wisconsin together form one of the premier, not-for-profit health systems in the United States. Advocate Aurora Health is nationally recognised for clinical expertise across the care continuum while leading health care transformation to drive value and reimagine the consumer experience.

Within Advocate Health Care is the Advocate Heart Institute with over 100 sites, where 350 specialists perform more than 20,000 heart procedures each year, the most in Illinois. They are a national leader in heart outcomes and pride themselves on pioneering the most advanced programs and technology.

The introduction of SOZO is being championed by Dr Ali Valika, with the aim of optimising fluid levels in Heart Failure Patients both in clinic and after discharge. He currently practices at Advocate Health Midwest Heart Specialists and is affiliated with Advocate Good Samaritan Hospital.

ImpediMed was able to leverage its existing footprint within the Advocate Aurora Health system to move forward with an initial Heart Failure Program. The Advocate Aurora Health system currently has 10 SOZO devices under a Lymphoedema Prevention Program.

"After the significant COVID-19 delays it is fantastic to initiate the SOZO heart failure program at such a highly respected/credentialed medical institution. We are looking forward to working with Dr. Valika and his team in advancing the use of SOZO and improving outcomes in the heart failure patients," commented Richard Carreon, Managing Director and CEO of ImpediMed. "We are expecting other hospitals to initiate SOZO heart failure programs shortly, adding to the clinical and reimbursement evidence required to underpin widespread commercialisation."

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.